Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools-Reference-Cited by-同舟云学术

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools

Published:2021-10-18 Issue:6 Volume:16 Page:823-838
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Castagnetti Fausto,Binotto Gianni,Capodanno Isabella,Billio Atto,Calistri Elisabetta,Cavazzini Francesco,Crugnola Monica,Gozzini Antonella,Gugliotta Gabriele,Krampera Mauro,Lucchesi Alessandro,Merli Anna,Miggiano Maria Cristina,Minotto Claudia,Poggiaspalla Monica,Salvucci Marzia,Scappini Barbara,Tiribelli Mario,Trabacchi Elena,Rosti Gianantonio,Galimberti Sara,Bonifacio Massimiliano

Funder

Novartis Farma SpA

Alma Mater Studiorum - Università di Bologna

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-021-00831-4.pdf

Reference107 articles.

1. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

2. Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.